Filed Pursuant to Rule 424(b)(3)
Registration No. 333-266763
PROSPECTUS SUPPLEMENT NO. 3
(To the Prospectus dated
September 7, 2022)
70,676,577 Shares of Common Stock
This prospectus supplement supplements the prospectus, dated September 7, 2022 (the Prospectus), which forms a part of our registration
statement on Form S-1 (No. 333-266763). This prospectus supplement is being filed to update and supplement the information in the Current Report on Form 8-K, filed with the Securities and Exchange Commission on October 27, 2022 (the Current Report). Accordingly, we have attached the Current Report to this prospectus supplement. The
Prospectus and this prospectus supplement relate to the offer and resale of (i) up to 70,289,880 shares (the CEF Shares) of our common stock, $0.0001 per share (the Common Stock), by B. Riley Principal Capital II, LLC
(the B. Riley Principal Capital II) and (ii) up to 386,697 shares (the Advisory Fee Shares and, together with the CEF Shares, the Shares) of Common Stock by B. Riley Securities, Inc. (BRS and,
together with B. Riley Principal Capital II, the Selling Stockholders). The CEF Shares included in the Prospectus consist of shares of Common Stock that we have issued or that we may, in our discretion, elect to issue and sell to B.
Riley Principal Capital II, from time to time after the date of the Prospectus, pursuant to a common stock purchase agreement we entered into with B. Riley Principal Capital II on July 20, 2022 (the Purchase Agreement), in
which B. Riley Principal Capital II has committed to purchase from us, at our direction, up to $100,000,000 of shares of our Common Stock, subject to terms and conditions specified in the Purchase Agreement. Under the applicable Nasdaq
rules, in no event may we issue to B. Riley Principal Capital II under the Purchase Agreement more than 70,289,880 shares of Common Stock, which number of shares is equal to approximately 19.99% of the shares of the Common Stock outstanding
immediately prior to the execution of the Purchase Agreement (the Exchange Cap) unless certain conditions are met. Concurrently with our execution of the Purchase Agreement on July 20, 2022, we issued 573,381 shares of Common Stock,
which are part of the CEF Shares included in the Prospectus, to B. Riley Principal Capital II as consideration for its irrevocable commitment to purchase shares of our Common Stock at our election in our sole discretion, from time to time
after the date of the Prospectus, upon the terms and subject to the satisfaction of the conditions set forth in the Purchase Agreement. See the section titled Committed Equity Financing for a description of the Purchase Agreement and the
section titled Selling Stockholders in the Prospectus for additional information regarding B. Riley Principal Capital II.
The Advisory Fee
Shares included in the Prospectus consist of shares of Common Stock that we have issued to BRS as an advisory fee in connection with our execution of two amended and restated bridge promissory notes on August 1, 2022, one with B. Riley
Commercial Capital, LLC and one with an affiliate of B. Riley Commercial Capital, LLC. Our Common Stock and Public Warrants are listed on the Nasdaq Global Select Market under the symbols CORZ and CORZW, respectively. On
October 26, 2022, the last reported sales price of our Common Stock was $1.01 per share and the last reported sales price of our Public Warrants was $0.22 per warrant.
This prospectus supplement should be read in conjunction with the Prospectus, including any amendments or supplements thereto, which is to be delivered with
this prospectus supplement. This prospectus supplement is qualified by reference to the Prospectus, including any amendments or supplements thereto, except to the extent that the information in this prospectus supplement updates and supersedes the
information contained therein.
This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the
Prospectus, including any amendments or supplements thereto.
We are an emerging growth company as defined under U.S. federal securities laws
and, as such, have elected to comply with reduced public company reporting requirements. The Prospectus complies with the requirements that apply to an issuer that is an emerging growth company.
Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled
Risk Factors beginning on page 12 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the
accuracy or adequacy of this prospectus supplement or the Prospectus. Any representation to the contrary is a criminal offense.
Prospectus
Supplement dated October 27, 2022